• Argenica shows promising results on lead drug ARG-007 for Alzheimers
  • The US FDA granted expanded approval for Anteris’ DurAVR THV study


In another win for Alzheimer sufferers, Argenica Therapeutics (ASX:AGN) has today shown that its lead drug, ARG-007, significantly inhibited one of the main causes of Alzheimer’s disease.

The AGN’s share price surged almost 30% on the news.

Argenica’s preclinical in-vitro study indicated that ARG-007 is able to inhibit human recombinant Amyloid-Beta (Abeta) aggregation.

Abeta aggregation is thought to be one of the main causes of Alzheimer’s disease, with the Abeta accumulation in senile plaques causing memory loss and confusion.

The in-vitro model provides important insights into the pathogenesis of Alzheimer’s Disease by simulating the disease in a less complex environment compared to in-vivo (in living organism) systems.

It also provides preliminary information on other possible protective roles of ARG-007 in Alzheimer’s disease.

“This is extremely encouraging data showing a potential new indication for ARG-007,” said Dr Liz Dallimore, Argenica’s CEO.

Dr Lizmore explained that Abeta aggregation in the brain plays a key role in initiating Alzheimer’s disease.

“Therefore a safe therapeutic drug that can reduce Abeta aggregation is a huge opportunity, and we look forward to continuing to progress this exciting opportunity into further animal studies.”

Over the last couple of years, there has been a resurgence in pharmaceutical companies launching new drugs for Alzheimer’s.

In September last year, US-based Biogen announced that its Phase 3 Clarity study on lecanemab was successful and showed a reduced cognitive decline in a population of 1,795 participants with Alzheimers.

Just a couple of weeks ago, Nasdaq listed Hoth Therapeutics reported positive proof-of-concept data for its Alzheimer’s disease (AD) drug HT-ALZ in a mouse model.


Anteris gets expanded FDA approval

The US FDA has granted expanded approval for Anteris Tech (ASX:AVR)’s DurAVRTM THV System study in “Subjects with Severe Aortic Stenosis”.

The expanded approval removes the previous conditions placed on the study, and will allow Anteris to accelerate certain activities related to study execution.

The DurAVRTM THV System is a ‘biomimetic’ aortic heart valve replacement device, and the world’s first single-piece transcatheter heart valve, made with the company’s patented ADAPT anti-calcification process and innovative tissue-shaping technology.

“The DurAVR THV clinical program continues to gather significant momentum with the removal of conditions by the FDA further paving the way for our ground-breaking technology,” said CEO, Wayne Paterson.

“We are excited to continue building our remarkable real-world evidence base amongst patients receiving DurAVR in the United States as we progress on our path to regulatory approval.”